There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD79B


CD79B Molecule Information

Name:B-cell antigen receptor complex-associated protein beta chain
Target Synonym:Ig-beta;CD79b;B29;IGB;Immunoglobulin-associated B29 protein;B-cell-specific glycoprotein B29;CD79B
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Approved

CD79B Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CDB-H5259 Human Human CD79B Protein, Fc Tag

CD79B Molecule Synonym Name


CD79B Molecule Background

B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.

CD79B References

CD79B Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Polatuzumab vedotin DCDS-4501A; FCU-2711; RG-7596; RO-5541077; RO-5541077-000 Approved Genentech, Seattle Genetics, Chugai POLIVY fda Diffuse large B cell lymphoma GENENTECH 2019-06-10 Diffuse large B cell lymphoma Details

CD79B Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Iladatuzumab vedotin DCDS-0780A; RO-7032005 Phase Ⅰ Roche Non-Hodgkin's lymphoma (NHL) Details
PRV-3279 PRV-3279; MGD-010; CD32BxCD-79B Phase Ⅱ MacroGenics, Provention Bio Autoimmune diseases, Systemic lupus erythematosus Details

This web search service is supported by Google Inc.